RAB44

mass-spec protein & survival
Survivalmass-specKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RAB44 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RAB44 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RAB44 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RAB44 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where RAB44 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
PDACOSQuartileIII,IV0.2470.977.0089view →
LSCCOSMedianAll1.0000.800.0441view →
HNSCOSQuartileAll0.9620.859.0311view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RAB44–PDAC (OS)

Kaplan–Meier survival curve for RAB44 mass-spec protein-high vs -low samples in PDAC.

Open the PDAC breakdown →

Exploration